Over the past decade, four landmark cardiovascular outcome trials have quietly rewritten how we think about cardiometabolic risk: LEADER (2016) Liraglutide cut MACE by 13%, CV death by 22%, and all-cause mortality by 15% in high-risk T2DM patients
Ruxolitinib (Opzelura) cream, a JAK inhibitor, is the first FDA-approved repigmentation therapy for non-segmental vitiligo (ages 12+)
Preventing Premature Aging Glutathione helps reduce oxidative stress, which accelerates the appearance of wrinkles and loss of skin elasticity
doi: 10.1038/nrendo.2014.29 38 SteinbergHOBrechtelGJohnsonAFinebergNBaronAD
Nutrient treatment should follow laboratory findings and the patients biochemical pattern
[DOI] [PubMed] [Google Scholar] 6.Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW